Skip to Content

Targiniq ER Approval History

  • FDA approved: Yes (First approved July 23rd, 2014)
  • Brand name: Targiniq ER
  • Generic name: naloxone and oxycodone
  • Dosage form: Extended-Release Tablets
  • Company: Purdue Pharma LP
  • Treatment for: Pain

Targiniq ER (naloxone and oxycodone) is an opioid antagonist and opioid analgesic combination in a long-acting abuse-deterrent formulation for the management of chronic severe pain.

Development History and FDA Approval Process for Targiniq ER

Jul 23, 2014Approval FDA Approves Targiniq ER Extended-Release Oxycodone with Abuse-Deterrent Properties
Nov 26, 2013FDA Accepts for Review Purdue Pharma’s New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCL Controlled-Release) Tablets CII

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.